

David C Jackson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1079274/publications.pdf>

Version: 2024-02-01

187
papers

6,813
citations

66315

42
h-index

88593

70
g-index

194
all docs

194
docs citations

194
times ranked

7700
citing authors

#	ARTICLE	IF	CITATIONS
1	Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 835.	1.8	15
2	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	2.0	1
3	Immune profiling of influenza-specific B and T cell responses in macaques using flow cytometry-based assays. <i>Immunology and Cell Biology</i> , 2021, 99, 97-106.	1.0	6
4	Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. <i>EBioMedicine</i> , 2021, 63, 103153.	2.7	76
5	Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features. <i>Clinical and Translational Immunology</i> , 2021, 10, e1258.	1.7	28
6	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. <i>Cell Reports Medicine</i> , 2021, 2, 100208.	3.3	115
7	TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs. <i>JCI Insight</i> , 2021, 6, .	2.3	15
8	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. <i>Nature Communications</i> , 2021, 12, 2037.	5.8	125
9	CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph. <i>Nature Communications</i> , 2021, 12, 2931.	5.8	20
10	Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patients. <i>Nature Communications</i> , 2021, 12, 2691.	5.8	34
11	Selecting and Using the Appropriate Influenza Vaccine for Each Individual. <i>Viruses</i> , 2021, 13, 971.	1.5	15
12	Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells. <i>Vaccine</i> , 2021, 39, 3940-3951.	1.7	8
13	The endogenous inflammatory reflex inhibits the inflammatory response to different immune challenges in mice. <i>Brain, Behavior, and Immunity</i> , 2021, 97, 371-375.	2.0	9
14	TLR2-mediated innate immune priming boosts lung anti-viral immunity. <i>European Respiratory Journal</i> , 2021, 58, 2001584.	3.1	16
15	Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population. <i>Vaccine</i> , 2020, 38, 597-607.	1.7	4
16	Vaccine-Specific Immune Responses against <i>Mycobacterium ulcerans</i> Infection in a Low-Dose Murine Challenge Model. <i>Infection and Immunity</i> , 2020, 88, .	1.0	11
17	High antibody titres induced by protein subunit vaccines using <i>Mycobacterium ulcerans</i> antigens Hsp18 and MUL_3720 with a TLR-2 agonist fail to protect against Buruli ulcer in mice. <i>PeerJ</i> , 2020, 8, e9659.	0.9	10
18	Geometry of a TLR2-Agonist-Based Adjuvant Can Affect the Resulting Antigen-Specific Immune Response. <i>Molecular Pharmaceutics</i> , 2019, 16, 2037-2047.	2.3	4

#	ARTICLE	IF	CITATIONS
19	Human CD8+ T cell cross-reactivity across influenza A, B and C viruses. <i>Nature Immunology</i> , 2019, 20, 613-625.	7.0	180
20	Tear film inflammatory cytokine upregulation in contact lens discomfort. <i>Ocular Surface</i> , 2019, 17, 89-97.	2.2	28
21	In Vivo Imaging of Bioluminescent <i>Mycobacterium ulcerans</i> : A Tool to Refine the Murine Buruli Ulcer Tail Model. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 1312-1321.	0.6	9
22	Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists. <i>Viral Immunology</i> , 2018, 31, 338-343.	0.6	10
23	Opinion: Making Inactivated and Subunit-Based Vaccines Work. <i>Viral Immunology</i> , 2018, 31, 150-158.	0.6	12
24	The Toll-Like Receptor 2 agonist PEG-Pam2Cys as an immunochemoprophylactic and immunochemotherapeutic against the liver and transmission stages of malaria parasites. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2018, 8, 451-458.	1.4	8
25	A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against <i>Mycobacterium tuberculosis</i> . <i>Journal of Translational Medicine</i> , 2018, 16, 279.	1.8	13
26	Modulating Contact Lens Discomfort With Anti-Inflammatory Approaches: A Randomized Controlled Trial. , 2018, 59, 3755.		31
27	PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8+ T cell responses. <i>Biomaterials</i> , 2017, 137, 61-72.	5.7	29
28	Salivary Blockade Protects the Lower Respiratory Tract of Mice from Lethal Influenza Virus Infection. <i>Journal of Virology</i> , 2017, 91, .	1.5	21
29	Structure–function relationships of protein–lipopeptide complexes and influence on immunogenicity. <i>Amino Acids</i> , 2017, 49, 1691-1704.	1.2	9
30	A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease. <i>Ophthalmology</i> , 2017, 124, 43-52.	2.5	120
31	Extrinsically derived TNF is primarily responsible for limiting antiviral CD8+ T cell response magnitude. <i>PLoS ONE</i> , 2017, 12, e0184732.	1.1	8
32	A lipidated peptide of <i>Mycobacterium tuberculosis</i> resuscitates the protective efficacy of BCG vaccine by evoking memory T cell immunity. <i>Journal of Translational Medicine</i> , 2017, 15, 201.	1.8	14
33	Competition within the virus-specific CD4 T cell pool limits the T follicular helper response after influenza infection. <i>Immunology and Cell Biology</i> , 2016, 94, 729-740.	1.0	9
34	Spirituality, spiritual need, and spiritual care in aged care: What the literature says. <i>Journal of Religion, Spirituality and Aging</i> , 2016, 28, 281-295.	0.5	30
35	A novel therapeutic strategy of lipidated promiscuous peptide against <i>Mycobacterium tuberculosis</i> by eliciting Th1 and Th17 immunity of host. <i>Scientific Reports</i> , 2016, 6, 23917.	1.6	19
36	Chemical Synthesis of Monomeric, Dimeric and Tetrameric Forms of the Ectodomain of Influenza Matrix 2 Protein. <i>European Journal of Organic Chemistry</i> , 2016, 2016, 1054-1059.	1.2	1

#	ARTICLE	IF	CITATIONS
37	Mapping the pulmonary environment of animals protected from virulent H1N1 influenza infection using the TLR2 agonist Pam 2 Cys. <i>Immunology and Cell Biology</i> , 2016, 94, 169-176.	1.0	9
38	Reducing the impact of influenza-associated secondary pneumococcal infections. <i>Immunology and Cell Biology</i> , 2016, 94, 101-108.	1.0	18
39	Establishment of memory CD8+ T cells with live attenuated influenza virus across different vaccination doses. <i>Journal of General Virology</i> , 2016, 97, 3205-3214.	1.3	17
40	Generation of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2Cys. <i>Frontiers in Immunology</i> , 2015, 6, 290.	2.2	8
41	Prior Population Immunity Reduces the Expected Impact of CTL-Inducing Vaccines for Pandemic Influenza Control. <i>PLoS ONE</i> , 2015, 10, e0120138.	1.1	10
42	Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses. <i>PLoS ONE</i> , 2015, 10, e0129768.	1.1	24
43	Bioactivity in an Aggrecan 32mer Fragment Is Mediated via Tolllike Receptor 2. <i>Arthritis and Rheumatology</i> , 2015, 67, 1240-1249.	2.9	76
44	A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate. <i>Vaccine</i> , 2015, 33, 3526-3532.	1.7	17
45	A single dose biodegradable vaccine depot that induces persistently high levels of antibody over a year. <i>Biomaterials</i> , 2015, 53, 50-57.	5.7	19
46	Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity. <i>MBio</i> , 2015, 6, e01024-15.	1.8	34
47	Establishment of functional influenza virus-specific CD8+ T cell memory pools after intramuscular immunization. <i>Vaccine</i> , 2015, 33, 5148-5154.	1.7	9
48	Challenges and solutions for a rational vaccine design for TB-endemic regions. <i>Critical Reviews in Microbiology</i> , 2015, 41, 389-398.	2.7	9
49	Different Arms of the Adaptive Immune System Induced by a Combination Vaccine Work in Concert to Provide Enhanced Clearance of Influenza. <i>PLoS ONE</i> , 2014, 9, e115356.	1.1	7
50	TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease. <i>Frontiers in Immunology</i> , 2014, 5, 79.	2.2	121
51	Considerations for the rapid deployment of vaccines against H7N9 influenza. <i>Expert Review of Vaccines</i> , 2014, 13, 1327-1337.	2.0	4
52	The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T cell responses. <i>Immunology and Cell Biology</i> , 2014, 92, 377-383.	1.0	28
53	The Influenza Virus-Specific CTL Immunodominance Hierarchy in Mice Is Determined by the Relative Frequency of High-Avidity T Cells. <i>Journal of Immunology</i> , 2014, 192, 4061-4068.	0.4	28
54	Preemptive priming readily overcomes structure-based mechanisms of virus escape. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 5570-5575.	3.3	18

#	ARTICLE	IF	CITATIONS
55	The design and proof of concept for a CD8 ⁺ T cell-based vaccine inducing cross-subtype protection against influenza A virus. <i>Immunology and Cell Biology</i> , 2013, 91, 96-104.	1.0	34
56	Impaired dendritic cell maturation in response to pandemic H1N109 influenza virus. <i>Journal of Clinical Virology</i> , 2013, 56, 310-315.	1.6	7
57	Lipidated promiscuous peptide augments the expression of MHC-II molecules on dendritic cells and activates T cells. <i>Indian Journal of Medical Research</i> , 2013, 138, 744-8.	0.4	0
58	Chitosan-based particles as biocompatible delivery vehicles for peptide and protein-based vaccines. <i>Procedia in Vaccinology</i> , 2012, 6, 74-79.	0.4	10
59	Electrostatic-mediated enhancement of protein antigen immunogenicity using charged TLR2-targeting lipopeptides. <i>Procedia in Vaccinology</i> , 2012, 6, 80-84.	0.4	0
60	A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic <i>Escherichia coli</i> . <i>Vaccine</i> , 2012, 30, 4800-4806.	1.7	24
61	Intranasal Administration of the TLR2 Agonist Pam2Cys Provides Rapid Protection against Influenza in Mice. <i>Molecular Pharmaceutics</i> , 2012, 9, 2710-2718.	2.3	96
62	Lipidated promiscuous peptides vaccine for tuberculosis-endemic regions. <i>Trends in Molecular Medicine</i> , 2012, 18, 607-614.	3.5	22
63	Chitosan Microparticles and Nanoparticles as Biocompatible Delivery Vehicles for Peptide and Protein-Based Immunocontraceptive Vaccines. <i>Molecular Pharmaceutics</i> , 2012, 9, 81-90.	2.3	95
64	Herpes Simplex Virus Antigens Directly Activate NK Cells via TLR2, Thus Facilitating Their Presentation to CD4 T Lymphocytes. <i>Journal of Immunology</i> , 2012, 188, 4158-4170.	0.4	61
65	Control of size dispersity of chitosan biopolymer microparticles and nanoparticles to influence vaccine trafficking and cell uptake. <i>Journal of Biomedical Materials Research - Part A</i> , 2012, 100A, 1859-1867.	2.1	22
66	Polyfunctional CD8 ⁺ T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope. <i>Antiviral Research</i> , 2012, 94, 168-178.	1.9	17
67	Induction of Multi-Functional T Cells in a Phase I Clinical Trial of Dendritic Cell Immunotherapy in Hepatitis C Virus Infected Individuals. <i>PLoS ONE</i> , 2012, 7, e39368.	1.1	8
68	Hepatitis C VLPs Delivered to Dendritic Cells by a TLR2 Targeting Lipopeptide Results in Enhanced Antibody and Cell-Mediated Responses. <i>PLoS ONE</i> , 2012, 7, e47492.	1.1	44
69	Lipidation of intact proteins produces highly immunogenic vaccine candidates. <i>Molecular Immunology</i> , 2011, 48, 490-496.	1.0	19
70	A Modular Approach to Assembly of Totally Synthetic Self-adjuvanting Lipopeptide-based Vaccines Allows Conformational Epitope Building. <i>Journal of Biological Chemistry</i> , 2011, 286, 12944-12951.	1.6	26
71	Precursor Frequency and Competition Dictate the HLA-A2-Restricted CD8 ⁺ T Cell Responses to Influenza A Infection and Vaccination in HLA-A2.1 Transgenic Mice. <i>Journal of Immunology</i> , 2011, 187, 1895-1902.	0.4	43
72	Soluble Proteins Induce Strong CD8 ⁺ T Cell and Antibody Responses through Electrostatic Association with Simple Cationic or Anionic Lipopeptides That Target TLR2. <i>Journal of Immunology</i> , 2011, 187, 1692-1701.	0.4	41

#	ARTICLE	IF	CITATIONS
73	Affinity Thresholds for Naive CD8+ CTL Activation by Peptides and Engineered Influenza A Viruses. <i>Journal of Immunology</i> , 2011, 187, 5733-5744.	0.4	49
74	Antigen-Driven Patterns of TCR Bias Are Shared across Diverse Outcomes of Human Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2011, 186, 901-912.	0.4	26
75	Promiscuous Peptide of 16 kDa Antigen Linked to Pam2Cys Protects Against <i>Mycobacterium tuberculosis</i> by Evoking Enduring Memory T-Cell Response. <i>Journal of Infectious Diseases</i> , 2011, 204, 1328-1338.	1.9	38
76	Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys. <i>Amino Acids</i> , 2010, 39, 471-480.	1.2	37
77	A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. <i>Immunology and Cell Biology</i> , 2010, 88, 605-611.	1.0	31
78	A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. <i>Journal of Hepatology</i> , 2010, 53, 599-607.	1.8	57
79	Identification of key residues involved in fibril formation by the conserved N-terminal region of <i>Plasmodium falciparum</i> merozoite surface protein 2 (MSP2). <i>Biochimie</i> , 2010, 92, 1287-1295.	1.3	15
80	Neopeptide Antibodies Against MMP-Cleaved and Aggrecanase-Cleaved Aggrecan. <i>Methods in Molecular Biology</i> , 2010, 622, 305-340.	0.4	21
81	Role of CD8+T-cell immunity in influenza infection: potential use in future vaccine development. <i>Expert Review of Respiratory Medicine</i> , 2009, 3, 523-537.	1.0	3
82	Resistance to Celiac Disease in Humanized HLA-DR3-DQ2-Transgenic Mice Expressing Specific Anti-Gliadin CD4+ T Cells. <i>Journal of Immunology</i> , 2009, 182, 7440-7450.	0.4	85
83	T Cell Allorecognition via Molecular Mimicry. <i>Immunity</i> , 2009, 31, 897-908.	6.6	232
84	Anti-drug vaccines to treat substance abuse. <i>Immunology and Cell Biology</i> , 2009, 87, 309-314.	1.0	48
85	T CD8 response in diverse outcomes of recurrent exposure to hepatitis C virus. <i>Immunology and Cell Biology</i> , 2009, 87, 464-472.	1.0	10
86	Lipopeptide vaccines illustrate the potential role of subtype-specific crossreactive T cells in the control of highly virulent influenza. <i>Influenza and Other Respiratory Viruses</i> , 2009, 3, 177-182.	1.5	12
87	Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response. <i>Clinical Immunology</i> , 2008, 128, 329-339.	1.4	18
88	Synthesis of Toll-Like Receptor-2 Targeting Lipopeptides as Self-Adjuvanting Vaccines. <i>Methods in Molecular Biology</i> , 2008, 494, 247-261.	0.4	25
89	Dendritic cell acquisition of epitope cargo mediated by simple cationic peptide structures. <i>Peptides</i> , 2008, 29, 881-890.	1.2	8
90	Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses. <i>Vaccine</i> , 2008, 26, 2570-2579.	1.7	20

#	ARTICLE	IF	CITATIONS
91	A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. <i>Vaccine</i> , 2008, 26, 4866-4875.	1.7	50
92	Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5850-5855.	3.3	137
93	Secondary Acylation of <i>Klebsiella pneumoniae</i> Lipopolysaccharide Contributes to Sensitivity to Antibacterial Peptides. <i>Journal of Biological Chemistry</i> , 2007, 282, 15569-15577.	1.6	95
94	Recent Advances with TLR2-Targeting Lipopeptide-Based Vaccines. <i>Current Protein and Peptide Science</i> , 2007, 8, 412-417.	0.7	30
95	The Context of Epitope Presentation Can Influence Functional Quality of Recalled Influenza A Virus-Specific Memory CD8+ T Cells. <i>Journal of Immunology</i> , 2007, 179, 2187-2194.	0.4	41
96	Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. <i>Vaccine</i> , 2007, 25, 92-101.	1.7	50
97	Totally synthetic peptide-based immunocontraceptive vaccines show activity in dogs of different breeds. <i>Vaccine</i> , 2007, 25, 7111-7119.	1.7	28
98	The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. <i>Molecular Immunology</i> , 2007, 44, 3724-3731.	1.0	31
99	T cell epitopes of the La/SSB autoantigen in humanized transgenic mice expressing the hLa class II haplotype DRB1*0301/DQB1*0201. <i>Arthritis and Rheumatism</i> , 2007, 56, 3387-3398.	6.7	21
100	A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus. <i>Hepatology</i> , 2007, 45, 911-920.	3.6	26
101	A partially structured region of a largely unstructured protein, <i>Plasmodium falciparum</i> merozoite surface protein 2 (MSP2), forms amyloid-like fibrils. <i>Journal of Peptide Science</i> , 2007, 13, 839-848.	0.8	30
102	Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes. <i>Immunology and Cell Biology</i> , 2007, 85, 169-173.	1.0	16
103	Simple Branched Arginine-Based Structures can Enhance the Cellular Uptake of Peptide Cargos. <i>International Journal of Peptide Research and Therapeutics</i> , 2007, 13, 431-437.	0.9	1
104	Intranasal Vaccination with a Lipopeptide Containing a Conformationally Constrained Conserved Minimal Peptide, a Universal T Cell Epitope, and a Self-Adjuvanting Lipid Protects Mice from Group A Streptococcus Challenge and Reduces Throat Colonization. <i>Journal of Infectious Diseases</i> , 2006, 194, 325-330.	1.9	72
105	Totally synthetic peptide-based vaccines that target dendritic cells and induce potent antibody or CTL responses. <i>International Congress Series</i> , 2006, 1289, 311-315.	0.2	3
106	Intranasal vaccination with a lipopeptide containing a minimal, conserved M-protein derived peptide and a self-adjuvanting lipid induces both systemic and mucosal immune responses in mice. <i>International Congress Series</i> , 2006, 1289, 316-319.	0.2	0
107	Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. <i>European Journal of Immunology</i> , 2006, 36, 770-778.	1.6	71
108	Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. <i>International Immunology</i> , 2006, 18, 1801-1813.	1.8	53

#	ARTICLE	IF	CITATIONS
109	Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes. <i>Antiviral Therapy</i> , 2006, 11, 1005-14.	0.6	11
110	Exploiting Information Inherent in Binding Sites of Virus-Specific Antibodies: Design of An HCV Vaccine Candidate Cross-Reactive with Multiple Genotypes. <i>Antiviral Therapy</i> , 2006, 11, 1005-1014.	0.6	15
111	Dendritic Cell Immunotherapy of Hepatitis C Virus Infection: Toxicology of Lipopeptide-Loaded Dendritic Cells. <i>International Journal of Peptide Research and Therapeutics</i> , 2005, 11, 223-235.	0.9	8
112	Lipid-based Self-Adjuvanting Vaccines. <i>Current Drug Delivery</i> , 2005, 2, 383-393.	0.8	41
113	Mutation of chicken anemia virus VP2 differentially affects serine/threonine and tyrosine protein phosphatase activities. <i>Journal of General Virology</i> , 2005, 86, 623-630.	1.3	21
114	Memory cytolytic T-lymphocytes: induction, regulation and implications for vaccine design. <i>Expert Review of Vaccines</i> , 2005, 4, 711-723.	2.0	5
115	Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. <i>Vaccine</i> , 2005, 23, 4427-4435.	1.7	18
116	Identification of dominant epitopes of synthetic immunocontraceptive vaccines that induce antibodies in dogs. <i>Vaccine</i> , 2005, 23, 4589-4597.	1.7	7
117	Neutralising Antibody, CTL and Dendritic Cell Responses to Hepatitis C Virus: A Preventative Vaccine Strategy. <i>Current Drug Targets</i> , 2004, 5, 41-56.	1.0	20
118	<i>Plasmodium falciparum</i> Merozoite Surface Protein 6 Is a Dimorphic Antigen. <i>Infection and Immunity</i> , 2004, 72, 2321-2328.	1.0	33
119	Effects on Rotavirus Cell Binding and Infection of Monomeric and Polymeric Peptides Containing $\hat{I}\pm 2\hat{I}^1$ and $\hat{I}\pm x\hat{I}^2$ Integrin Ligand Sequences. <i>Journal of Virology</i> , 2004, 78, 11786-11797.	1.5	27
120	A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15440-15445.	3.3	226
121	Bypassing luminal barriers, delivery to a gut addressin by parenteral targeting elicits local IgA responses. <i>International Immunology</i> , 2004, 16, 1613-1622.	1.8	14
122	An Insect Antibacterial Peptide-Based Drug Delivery System. <i>Molecular Pharmaceutics</i> , 2004, 1, 220-232.	2.3	35
123	Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. <i>Journal of Clinical Virology</i> , 2004, 30, 283-290.	1.6	27
124	Single step enrichment of blood dendritic cells by positive immunoselection. <i>Journal of Immunological Methods</i> , 2003, 274, 47-61.	0.6	40
125	Immune responses in hepatitis C virus infection: The role of dendritic cells. <i>Immunology and Cell Biology</i> , 2003, 81, 63-66.	1.0	9
126	Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. <i>Immunology and Cell Biology</i> , 2003, 81, 67-72.	1.0	26

#	ARTICLE	IF	CITATIONS
127	Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design. <i>Journal of Peptide Science</i> , 2003, 9, 255-281.	0.8	59
128	Analysis of Immunological Nonresponsiveness to the 19-Kilodalton Fragment of Merozoite Surface Protein 1 of <i>Plasmodium yoelii</i> : Rescue by Chemical Conjugation to Diphtheria Toxoid (DT) and Enhancement of Immunogenicity by Prior DT Vaccination. <i>Infection and Immunity</i> , 2003, 71, 5700-5713.	1.0	23
129	Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. <i>Journal of Clinical Investigation</i> , 2003, 111, 1365-1371.	3.9	89
130	Highly Immunogenic and Totally Synthetic Lipopeptides as Self-Adjuvanting Immunocontraceptive Vaccines. <i>Journal of Immunology</i> , 2002, 169, 4905-4912.	0.4	172
131	Chicken Anemia Virus VP2 Is a Novel Dual Specificity Protein Phosphatase. <i>Journal of Biological Chemistry</i> , 2002, 277, 39566-39573.	1.6	102
132	A 320-Kilobase Artificial Chromosome Encoding the Human HLA DR3-DQ2 MHC Haplotype Confers HLA Restriction in Transgenic Mice. <i>Journal of Immunology</i> , 2002, 168, 3050-3056.	0.4	29
133	Induction of Long-Term Memory CD8 + T Cells for Recall of Viral Clearing Responses against Influenza Virus. <i>Journal of Virology</i> , 2002, 76, 4212-4221.	1.5	77
134	Identification of antigenically active tryptic fragments of apical membrane antigen-1 (AMA1) of <i>Plasmodium chabaudi</i> malaria: strategies for assembly of immunologically active peptides. <i>Vaccine</i> , 2002, 20, 3477-3484.	1.7	6
135	Definition of T cell epitopes within the 19â€ƒkDa carboxylterminal fragment of <i>Plasmodium yoelii</i> merozoite surface protein 1 (MSP119) and their role in immunity to malaria. <i>Parasite Immunology</i> , 2002, 20, 263-278.	0.7	28
136	Reduced Antigenicity of the Hepatitis B Virus HBsAg Protein Arising as a Consequence of Sequence Changes in the Overlapping Polymerase Gene That Are Selected by Lamivudine Therapy. <i>Virology</i> , 2002, 293, 305-313.	1.1	480
137	Assembly of synthetic peptide vaccines by chemoselective ligation of epitopes: influence of different chemical linkages and epitope orientations on biological activity. <i>Vaccine</i> , 2001, 19, 3843-3852.	1.7	37
138	Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus. <i>Immunology</i> , 2001, 104, 58-66.	2.0	48
139	Differential effect of CD8+ and CD8â€ƒ dendritic cells in the stimulation of secondary CD4+ T cells. <i>International Immunology</i> , 2001, 13, 465-473.	1.8	49
140	New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. <i>Nature Medicine</i> , 2000, 6, 455-459.	15.2	147
141	The geometry of synthetic peptide-based immunogens affects the efficiency of T cell stimulation by professional antigen-presenting cells. <i>International Immunology</i> , 2000, 12, 527-535.	1.8	27
142	Multi-epitope schistosome vaccine candidates tested for protective immunogenicity in mice. <i>Vaccine</i> , 2000, 19, 103-113.	1.7	50
143	Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens. <i>Vaccine</i> , 2000, 18, 1031-1039.	1.7	50
144	Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. <i>International Immunology</i> , 1999, 11, 569-576.	1.8	28

#	ARTICLE	IF	CITATIONS
145	Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines. <i>International Immunology</i> , 1999, 11, 1103-1110.	1.8	53
146	Mice lacking the transcription factor subunit Rel can clear an influenza infection and have functional anti-viral cytotoxic T cells but do not develop an optimal antibody response. <i>International Immunology</i> , 1999, 11, 1431-1439.	1.8	54
147	Synthetic peptides induce antibodies in sheep against <i>Taenia ovis</i> . <i>International Journal of Peptide Research and Therapeutics</i> , 1999, 6, 303-312.	0.1	0
148	Synthetic peptides induce antibodies in sheep against <i>Taenia ovis</i> . <i>International Journal of Peptide Research and Therapeutics</i> , 1999, 6, 303-312.	0.1	4
149	Synthetic peptide antigens induce antibodies to <i>Taenia ovis</i> oncospheres. <i>Vaccine</i> , 1999, 17, 1506-1515.	1.7	6
150	Preparation and properties of totally synthetic immunogens. <i>Vaccine</i> , 1999, 18, 355-361.	1.7	24
151	The antigenic and immunogenic properties of synthetic peptide immunocontraceptive vaccine candidates based on gamete antigens. <i>Vaccine</i> , 1999, 18, 416-425.	1.7	6
152	Immunopotential of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. <i>Vaccine</i> , 1998, 16, 2058-2068.	1.7	25
153	Polymerization of Unprotected Synthetic Peptides: A View toward Synthetic Peptide Vaccines. <i>Journal of the American Chemical Society</i> , 1997, 119, 1183-1188.	6.6	49
154	Free radical induced polymerization of synthetic peptides into polymeric immunogens. <i>Vaccine</i> , 1997, 15, 1697-1705.	1.7	45
155	Analysis of the interaction between a synthetic peptide of influenza virus hemagglutinin and monoclonal antibodies using an optical biosensor. <i>Molecular Immunology</i> , 1996, 33, 659-670.	1.0	33
156	The assembly and immunological properties of non-linear synthetic immunogens containing T-cell and B-cell determinants. <i>Vaccine</i> , 1996, 14, 553-560.	1.7	34
157	Synthesis of a New Template with a Built-in Adjuvant and Its Use in Constructing Peptide Vaccine Candidates Through Polyoxime Chemistry. <i>Journal of Peptide Science</i> , 1996, 2, 66-72.	0.8	32
158	Manipulation of the helper T cell response to influence antigenic competition occurring with a multivalent vaccine. <i>Immunology and Cell Biology</i> , 1996, 74, 81-89.	1.0	10
159	Defence against the immune barrage: Helminth survival strategies. <i>Immunology and Cell Biology</i> , 1996, 74, 564-574.	1.0	47
160	A synthetic peptide-based polyoxime vaccine construct of high purity and activity. <i>Molecular Immunology</i> , 1995, 32, 1031-1037.	1.0	49
161	Immunological parameters associated with antigenic competition in a multivalent footrot vaccine. <i>Vaccine</i> , 1995, 13, 1649-1657.	1.7	42
162	Synthesis and conformational analysis of N-glycopeptides that contain extended sugar chains. <i>Tetrahedron</i> , 1994, 50, 2373-2390.	1.0	34

#	ARTICLE	IF	CITATIONS
163	Conserved Determinants for CD4+ T Cells within the Light Chain of the H3 Hemagglutinin Molecule of Influenza Virus. <i>Virology</i> , 1994, 198, 613-623.	1.1	27
164	Glycosylation of a Synthetic Peptide Representing a T-Cell Determinant of Influenza Virus Hemagglutinin Results in Loss of Recognition by CD4+ T-Cell Clones. <i>Virology</i> , 1994, 199, 422-430.	1.1	30
165	Antigenic competition in a multivalent foot rot vaccine. <i>Vaccine</i> , 1994, 12, 457-464.	1.7	52
166	peptide probes. <i>Molecular Immunology</i> , 1994, 31, 289-299.	1.0	0
167	A study of the advantages and limitations of immunoblotting procedures for the detection of antibodies against influenza virus. <i>Electrophoresis</i> , 1993, 14, 926-936.	1.3	5
168	Modulation of CD4+ T-Cell Recognition of Influenza Hemagglutinin by Carbohydrate Side Chains Located Outside a T-Cell Determinant. <i>Virology</i> , 1993, 192, 282-289.	1.1	24
169	Quantitative analysis of the interaction between lysozyme and monoclonal antibody D1.3. <i>Molecular Immunology</i> , 1993, 30, 47-54.	1.0	8
170	Western blot analysis of antibody responses to influenza virion proteins. <i>Immunology and Cell Biology</i> , 1992, 70, 181-191.	1.0	13
171	Probing the idiotype/anti-idiotype antibody interaction with a set of synthetic peptide homologues. <i>Immunology Letters</i> , 1991, 28, 213-218.	1.1	4
172	Extension of a minimal T cell Determinant allows relaxation of the requirement for particular residues within the determinant. <i>International Immunology</i> , 1991, 3, 1307-1313.	1.8	14
173	The stoichiometry of binding between monoclonal antibody molecules and the hemagglutinin of influenza virus. <i>Virology</i> , 1990, 179, 768-776.	1.1	11
174	Immunochemical and Crystallographic Studies on the Interaction between Antibody and a Synthetic Peptide of Influenza Hemagglutinin. , 1990, , 75-85.		0
175	Simultaneous binding of two monoclonal antibodies to epitopes separated in sequence by only three amino acid residues. <i>Molecular Immunology</i> , 1988, 25, 465-471.	1.0	21
176	Antigenic determinants of influenza virus hemagglutinin XII. The epitopes of a synthetic peptide representing the C-terminus of HA1. <i>Virology</i> , 1986, 155, 625-632.	1.1	42
177	Antigenic determinants of influenza virus hemagglutinin XI. Conformational changes detected by monoclonal antibodies. <i>Virology</i> , 1985, 145, 72-83.	1.1	34
178	Conformational changes in influenza virus haemagglutinin and its monomer detected by monoclonal antibodies. <i>Vaccine</i> , 1985, 3, 175-181.	1.7	10
179	Antibodies elicited by influenza virus hemagglutinin fail to bind to synthetic peptides representing putative antigenic sites. <i>Molecular Immunology</i> , 1985, 22, 145-154.	1.0	42
180	Changes in the antigenicity of the hemagglutinin molecule of H3 influenza virus at acidic pH. <i>Virology</i> , 1983, 126, 587-599.	1.1	119

#	ARTICLE	IF	CITATIONS
181	Chemical and antigenic characterization of the carbohydrate side chains of an Asian (N2) influenza virus neuraminidases. <i>Virology</i> , 1983, 126, 370-375.	1.1	27
182	Antigenic determinants of influenza virus hemagglutinin IX. The carbohydrate side chains from an Asian strain. <i>Molecular Immunology</i> , 1982, 19, 329-338.	1.0	20
183	Antigenic activity of a synthetic peptide comprising the "loop" region of influenza virus hemagglutinin. <i>Virology</i> , 1982, 120, 273-276.	1.1	30
184	Antigenic determinants of influenza virus hemagglutinin VII. The carbohydrate side chains of A/Memphis/102/72 hemagglutinin heavy chain which cross-react with host antigen. <i>Virology</i> , 1981, 108, 71-79.	1.1	17
185	ANTIGENIC CARBOHYDRATE DETERMINANTS ON INFLUENZA HEMAGGLUTININ. , 1981, , 233-252.		4
186	Detection and isolation of an Ia glycoprotein antigen from mouse serum. <i>Immunogenetics</i> , 1977, 4, 267-279.	1.2	10
187	Low-molecular-weight Ia antigens in normal mouse serum. <i>Immunogenetics</i> , 1976, 3, 455-463.	1.2	33